BioCentury
ARTICLE | Strategy

TriGenix done in by a string of bad luck

November 14, 1994 8:00 AM UTC

Noteworthy

TriGenix Inc. is planning on closing its doors, a victim both of D. Blech's financial problems and the failure of Celtrix Pharmaceuticals Inc.'s Phase III BetaKine trial to show efficacy in macular holes...